FALCONS FORTUNES

Falcons' Fortunes - FACIT's Annual Pitch Competition - Tuesday, February 4, 2020

Opportunity for Ontario Cancer Researchers to vie for the
"Ernsting Entrepreneurship Award"

Falcons' Fortunes (based on the popular TV series Dragons' Den) invites Ontario-based entrepreneurs working in the oncology space to pitch innovative research ideas to an external panel of judges. Hosted by the FACIT Falcons (i.e. the FACIT team), this annual event offers $50,000 in Prospects funding to invest in the most promising oncology research idea. While the research idea should be novel and sound, the competition is for the best pitch i.e. the presentation that best convinces the investor judging panel on the value of the idea and how $50,000 would improve and/or better illustrate the potential, and if possible commercial, value of the innovative idea itself.

The Falcons’ Fortunes event endeavors to enhance, support and celebrate a culture of commercialization in Ontario, such as the cultivation of skill sets that enable ideas to be successfully pitched to investors and promotion of entrepreneurial spirit.

Eligibility:

The Falcons’ Fortunes pitch competition is open to any Ontario-based entrepreneurial researcher (e.g. academia, research institutions, research hospitals, startups, etc.) working in the oncology space. Joint pitches from up to two researchers are also eligible. Basically, anyone with the entrepreneurial itch should participate!

How to participate:

Send an email to Lisa Milestone by Friday, November 22nd, 2019 to indicate your intent to participate. An abstract of your pitch idea must be submitted by Friday, December 6th, 2019 (instructions on submitting abstracts will be emailed to participants). A maximum of 6 participants will be selected by Thursday, December 19th, 2019 to deliver their pitches on February 4th, 2020.

Summary of Timelines:

Notice of intent to participate - email RSVP sufficient Fri, Nov 22
Submission of pitch abstracts Fri, Dec 6
Announcement of selected pitch finalists Thurs, Dec 19
Pitch preparation webinar Wed, Jan 15
1:1 practice sessions for finalists Mon, Jan 27
Falcons' Fortunes event Tues, Feb 4

Audience Registration:

Audience registration opens Tuesday, January 7, 2020. Seating is limited.

Questions?

For more details about the competition, please download the Competition Overview document or contact Lisa Milestone for more information.

Past Winners:

2019: A radially expandable access port to maximize the potential of laparoscopic surgical oncology

Recognizing a real unmet need, Xpan is developing expandable surgical access ports that aim to increase safety and efficiency of minimally invasive surgeries.

 

2019: A radially expandable access port to maximize the potential of laparoscopic surgical oncology2019: A radially expandable access port to maximize the potential of laparoscopic surgical oncology


2018: ReFilx™ – A regenerative filler matrix for breast cancer patients

ReFilx™ is a novel polymeric soft tissue filler that provides breast cancer patients with a cosmetically superior, minimally-invasive and cost-effective solution for the permanent restoration of breast defects following lumpectomy.

2018: ReFilx™ – A regenerative filler matrix for breast cancer patients2018: ReFilx™ – A regenerative filler matrix for breast cancer patients


2017: Development of a Multi-mechanistic Vaccinia Virus-based Platform for the Treatment of Pancreatic Cancer

The novel platform delivers sustained and amplified viral-mediated cell killing specific to pancreatic cancer (PCa) via the production of PCa cell-targeted amiR-containing exosomes.

2017: Development of a Multi-mechanistic Vaccinia Virus-based Platform for the Treatment of Pancreatic Cancer2017: Development of a Multi-mechanistic Vaccinia Virus-based Platform for the Treatment of Pancreatic Cancer


2016: MY-osto-ME

An economical port, bag and belt system for urostomy patients that aims to reduce their rate of complications, facilitate application, and reduce social stigma; overall helping improve the quality of life of bladder cancer patients.

2016: MY-osto-ME2016: MY-osto-ME